Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$326.77
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,131,600
Last Update: 10/21/14 - 4:00 PM EDT
Volume: 0
YTD Performance: 16.88%
Open: $0.00
Previous Close: $326.77
52 Week Range: $230.25 - $358.89
Oustanding Shares: 236,144,705
Market Cap: 73,537,822,584
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 11 11
Moderate Buy 1 1 1 1
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.76 1.65 1.65 1.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 34.64
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
34.64 34.60 27.46
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.02% 34.43% 200.23%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $3.22 $3.41 $12.66 $16.06
Number of Analysts 2 2 2 2
High Estimate $3.53 $3.66 $13.13 $16.77
Low Estimate $2.91 $3.15 $12.20 $15.35
Prior Year $2.34 $2.33 $8.93 $12.66
Growth Rate (Year over Year) 37.61% 46.14% 41.83% 26.81%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Dick Arms

 | Sep 25, 2014 | 7:00 AM EDT

Use one short and one buy.

updateMorgan Stanley Healthcare Conf.

Sep 8, 2014 | 7:12 AM EDT

Morgan Stanley Healthcare Conference

By

Timothy Collins

 | Aug 26, 2014 | 11:54 AM EDT
Checking two biotech charts.
By

Jim Cramer

 | Aug 13, 2014 | 1:18 PM EDT

Biotech stocks are thriving in a slower-growth, low-inflation world.

By

Doug Kass

 | Aug 12, 2014 | 12:58 PM EDT
Take the ice bucket challenge?
By

Scott Redler

 | Aug 7, 2014 | 7:41 PM EDT

As the action continues to the downside, we have no long positions on the table.

By

Scott Redler

 | Aug 4, 2014 | 7:50 PM EDT

For the first time in months, we have no long positions on the table.

bullishBiogen Idec price target raised at Jefferies

Jul 24, 2014 | 8:10 AM EDT

BIIB price target raised from $380 to $410, Jefferies said. Buy rating. Company beat estimates due to strong Tysabri and Tecfidera sales.

bullishBiogen Idec numbers raised at Credit Suisse

Jul 24, 2014 | 7:48 AM EDT

Shares of BIIB now seen reaching $425, according to Credit Suisse. Estimates also increased, as management guided to higher Tecfidera growth. Outperform rating. 

By

Jim Cramer

 | Jul 24, 2014 | 6:38 AM EDT

In theory there should be plenty of shorting opportunities.

As the SPX 500 has put on over 120 handles from the low Wednesday there is a marked change...
As the reports that the ECB is considering buying corporate bonds increase, a report into ...
Impressive and very broad based rally as tone has changed in market since middle of last w...
Conclusion TWTR is growing revenue faster than any other peer. TWTR has worse net income m...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.